Charles River Finalizes Agreement With CELLphenomics, Expanding 3D In Vitro Services For Cancer Therapy Drug Screening
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (NYSE:CRL) has finalized an agreement with CELLphenomics to expand its 3D in vitro testing services for cancer therapy drug screening. CELLphenomics' PD3D® tumor model platform will enhance Charles River's offerings, providing clients access to over 500 complex in vitro models from more than 20 tumor entities. The partnership will also allow CELLphenomics to utilize Charles River's database of over 700 tumor models for developing PD3D models, increasing the translational relevance of both companies' platforms.
December 12, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River's agreement with CELLphenomics to expand 3D in vitro services for cancer drug screening could enhance its service offerings and potentially increase its market share in the oncology research sector.
The partnership with CELLphenomics is likely to have a positive impact on Charles River's stock in the short term as it expands the company's capabilities in the growing field of oncology research and drug screening. Access to CELLphenomics' extensive biobank and proprietary PD3D platform could enhance Charles River's competitive edge and appeal to clients, potentially leading to increased revenue streams.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80